AA
KYMR icon

ALPS Advisors’s Kymera Therapeutics KYMR Stock Holding History

ALPS Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.54M Buy
66,457
+1,734
+3% +$137K 0.03% 235
2025
Q4 		$5.04M Buy
+64,723
New +$4.37M 0.03% 246

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ALPS Advisors's KYMR Position: Q1 2026 in Review

ALPS Advisors increased its Kymera Therapeutics (KYMR) stake by 2.7% in Q1 2026, buying an estimated $137K and bringing the position to 66,457 shares worth $5.54M. The position accounts for 0.03% of the portfolio, ranked #235.

ALPS Advisors first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • ALPS Advisors held 66,457 shares of Kymera Therapeutics worth $5.54M as of Q1 2026.
  • ALPS Advisors bought 1,734 Kymera Therapeutics shares in Q1 2026, an estimated $137K.
  • Kymera Therapeutics made up 0.03% of ALPS Advisors's portfolio in Q1 2026, its #235 holding.
  • ALPS Advisors first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.